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We investigated the protective effects of a selective a1A-adrenoceptor antagonist, silodosin (Silod) on
urinary bladder function in cyclophosphamide (CYP)-induced cystitis rats, with and without desensiti-
zation of the capsaicin (CAP)-sensitive afferent nerve pathway. Male Wistar rats (310e400 g) were
pretreated with Silod (0, 100, or 300 mg/kg/day, p.o.) for 1 week before cystometry, and were adminis-
tered either CYP (150 mg/kg, i.p.) or saline 2 days before the experiment. In another experiment, the rats
were treated with CAP (125 mg/kg, s.c.) 4 days before the cystometry. The rat bladders were harvested,
weighed, and evaluated histologically. The cystometric evaluation showed signiﬁcant reductions in the
intercontraction interval (ICI), single voided volume (SVV), and bladder compliance in CYP-treated rats
compared to those in the vehicle-treated rats. High-dose Silod or CAP treatment signiﬁcantly increased
the ICI and SVV in the CYP rats. However, high-dose Silod treatment did not increase the ICI and SVV in
CAP-treated CYP rats. Treatment with Silod did not improve the bladder weight, edema, and leukocyte
inﬁltration resulting from the CYP-induced bladder inﬂammation. These data suggest that blockade of
a1-adrenoceptors by Silod inhibited the CAP-sensitive afferent pathway in rats with cystitis.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Lower urinary tract symptoms (LUTS) consist of storage, voiding,
and post-micturition symptoms of the lower urinary tract. Alpha1-
adrenoceptor (a1-AR) antagonists are used as the ﬁrst-line drugs
for the treatment of LUTS in patients with benign prostatic hyper-
plasia (BPH). a1-AR antagonists have been reported to improve
voiding and storage symptoms in men with BPH/LUTS (1,2). a1-AR
antagonists are thought to alleviate voiding symptoms by relaxing
the prostate smooth muscle and decreasing urethral resistance;
however, the precise mechanism by which a1-AR antagonists
improve storage symptoms is not well understood. One of the
proposed mechanisms underlying the a1-AR antagonist-induced
improvement of storage symptoms is their effect on a1-ARs in
the sacral spinal cord (3). Some a1-ARs are also expressed in
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d/4.0/).the activation of a1-ARs could contribute to the signaling of irri-
tative and nociceptive responses.
The a1-ARs are subdivided into a1A-, a1B-, and a1D-AR sub-
types (4). In particular, a1A- and a1D-ARs are known to play
important roles in the lower urinary tract. Silodosin (Silod) is a
highly selective a1A-AR antagonist, which was previously shown to
suppress detrusor overactivity in a rat model of BPH induced by
testosterone and 17b-estradiol (5). Yazaki et al. reported that
chronic administration of Silod decreased urinary frequency in rats
withmechanical bladder outlet obstruction (BOO) (6). In that study,
Silod suppressed BOO-induced upregulation of c-Fos in the spinal
cord, which is a marker of increased afferent input from mecha-
noreceptors in the lower urinary tract (6). These data suggest that
a1-AR antagonists inhibit the afferent input from obstructed
bladders to the spinal cord.
Bladder inﬂammation causes various functional changes in the
production of inﬂammatory cytokines and in the bladder afferent
pathways, which might contribute to the hyperexcitability of af-
ferents and then induce frequent urination (7). Cyclophosphamide
(CYP) is a chemotherapeutic drug that induces hemorrhagic cystitis
and increases the frequency of urination. These effects are caused
by acrolein, a toxic metabolite of CYP, which causes bladdernese Pharmacological Society. This is an open access article under the CC BY-NC-ND
N. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 71e7772inﬂammation and activates nociceptive sensory neurons (4). Thus,
CYP-induced bladder inﬂammation is a well-established model of
interstitial cystitis/painful bladder syndrome. A previous study has
shown that chronic treatment with the a1A-AR antagonist, tam-
sulosin signiﬁcantly decreases CYP-induced c-Fos expression in the
rat spinal cord (8).
In the present study, we examined the protective effects of Silod
on urinary bladder function in rats with CYP-induced cystitis, with
or without desensitization of the capsaicin (CAP)-sensitive afferent
pathway. In addition, we investigated the mechanism by which a1-
AR blockade affects the afferent pathway and decreases urinary
frequency.2. Materials and methods
2.1. Drugs and chemicals
The Silod and CAP were purchased from Wako Pure Chemical
(Osaka, Japan) while CYP monohydrate and urethane were ob-
tained from SigmaeAldrich (St. Louis, MO, USA). All other chemicals
were purchased from Nacalai Tesque (Kyoto, Japan) and were of
guaranteed reagent grade.2.2. Animals and treatment procedures
The experimental protocols were approved by the Institutional
Animal Care and Use Committee of Kochi University (Permit
Numbers: H-68 and I-8) and were conducted in accordance with
the Guidelines for Proper Conduct of Animal Experiments issued by
the Ministry of Education, Culture, Sports, Science, and Technology
of Japan. Furthermore, this study was reported in accordance with
the Animal Research Reporting In Vivo Experiments (ARRIVE)
guidelines (9).
The male Wistar rats (310e400 g) used in the study were ob-
tained from Japan SLC, Inc., (Hamamatsu, Japan). All the animals
were housed under identical temperature and humidity conditions
with a 14-/10-h light/dark cycle and were given access to food and
water ad libitum. The rats were treated with Silod (0, 100, or 300 mg/
kg/day, p.o. in 0.5% methyl cellulose as the solvent [vehicle]) at a
volume of 2 mL/kg once daily for 1 week prior to the urodynamic
evaluation. The p.o. dose of Silod recommended by the US Food and
Drug Administration (FDA) is 8 mg once daily and, therefore, we
adopted doses of 100 and 300 mg/kg p.o. (10). Subsequently, 2 days
before the experiments commenced, either CYP (150 mg/kg, i.p.) or
saline was administered to the rats. CAP (125 mg/kg) in divided
doses (25 and 50 mg/kg administered 12 h apart on day 1 and
50 mg/kg administered on day 2) or the vehicle was subcutane-
ously injected for 2 consecutive days to desensitize the afferents 4
days before the urodynamic evaluation. CAP was administered at
2 mL/kg as a solution containing 10% ethanol, 10% Tween 80, and
80% saline.
The animals were divided into eight groups and treated as fol-
lows: [1] vehicle-treated saline (n ¼ 8), [2] vehicle-treated CYP
(n ¼ 8), [3] Silod (100 mg/kg)-treated CYP (n ¼ 8), [4] Silod (300 mg/
kg)-treated CYP (n ¼ 7), [5] CAP-untreated vehicle and CYP (n ¼ 9),
[6] CAP-untreated Silod (300 mg/kg) and CYP (n ¼ 9), [7] CAP-
treated vehicle and CYP (n ¼ 9), [8] CAP-treated Silod (300 mg/kg)
and CYP groups (n ¼ 9).
The continuous cystometry was performed under urethane
anesthesia, the rats were euthanized immediately by administra-
tion of an overdose of sodium pentobarbital (80 mg/kg, i.p.), and
then their bladders were removed and weighed. The bladders were
cut into small strips on ice for histological evaluation or stored
at 80 C until the biochemical analyses.2.3. Eye wipe test
An eye wipe test was performed on each rat immediately before
anesthesia was induced for the urodynamic evaluation (Section
2.4.) to assess the efﬁcacy of afferent desensitization. A 100-mg/mL
drop of CAP solution was instilled into one eye, and the number of
defensive wiping movements was counted. After the test, the eye
was irrigated with saline and the rats were anesthetized for the
urodynamic evaluation (11). The experiment was performed in
groups [5]e[8].
2.4. Cystometric studies
The cystometry was performed in all animals as previously re-
ported (10). Initially, anesthesia was induced using urethane (1.0 g/
kg, i.p.). The abdomen was then opened using a lower midline
incision, and the bladder was exposed and emptied. An intravesical
catheter was connected via a three-way stopcock to an external
pressure transducer (DX-100 S591, Nihon Kohden Corporation,
Tokyo, Japan) and an infusion pump (5200, TOP Corporation, Tokyo,
Japan) for the measurement of intravesical pressure and infusion of
saline into the bladder, respectively. Subsequently, a 22-G catheter
was inserted into the apex of the bladder dome, and the rats were
left undisturbed for 30 min for bladder stabilization. Then, a
continuous cystometry was performed using physiological saline
(0.9% NaCl) at a constant ﬂow rate of 12 mL/h. After stabilization for
60 min, the cystometric parameters were calculated from mictu-
rition cycles obtained over 30 min. The maximum voiding pressure
(MVP, the maximum intravesical pressure during micturition),
bladder compliance (BC), and intercontraction interval (ICI) were
evaluated. The ﬂuid voided from the urethrawas also collected, and
the volume (single voided volume [SVV]) was measured. At the end
of the cystometry, the saline infusion was stopped after conﬁrming
the micturition and post-void residual urine volume (RV) were
collected using the intravesical catheter. The experiment was per-
formed in groups [1]e[8].
2.5. Histological examination
Strips of bladder tissue were ﬁxed in 10% formalin, embedded in
parafﬁn, tissue sections (5-mm thick) were cut from the parafﬁn
blocks, and then stained with hematoxylin and eosin (H&E) for
microscopic examination (magniﬁcation, 200). The histological
evaluation was performed using light microscopy by blinded in-
vestigators according to the procedure used in a previous study
(12). To evaluate the edema, each tissue slice was divided into four
sections and the edema in each sectionwas scored as 0 (no edema),
1 (slight edema), 2 (moderate edema with the mucosal
layer < twice its initial size), or 3 (severe edema with the mucosal
layer > twice its initial size). The scores for all four sections were
summed up, divided by 12, and then multiplied by 100. Further-
more, each tissue section was divided into eight sections, and the
leukocyte inﬁltration in each section was scored as 0 (no extra-
vascular leukocytes), 1 (<20 leukocytes), 2 (20e45 leukocytes), or 3
(>45 leukocytes), respectively. The scores for all eight sections were
summed up, divided by 24, and then multiplied by 100. The
experiment was performed in groups [1]e[4].
2.6. Protein assay of bladder homogenates
After thawing, the bladder pieces were homogenized in lysis
buffer, which was phosphate-buffered saline (PBS, pH 7.4) con-
taining 0.05% NP-40 (MP Biomedicals, LLC, Santa Ana, CA, USA) and
proteinase inhibitors (cOmplete tablets, Mini; Roche, Basel,
Switzerland). The homogenates were centrifuged at 10,000  g for
Fig. 1. Representative traces of in vivo continuous cystometry in rats.
Vehicle þ Saline: rats were treated with vehicle (p.o.) and saline (i.p.); Vehicle þ CYP:
vehicle (p.o.) and 150 mg/kg CYP (i.p.); Silod100 þ CYP: 100 mg/kg silodosin (p.o.) and
150 mg/kg CYP (i.p.); Silod300 þ CYP: 300 mg/kg silodosin (p.o.) and 150 mg/kg CYP
(i.p.); Vehicle: 0.5% methyl cellulose; CYP: cyclophosphamide.
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at 80C for further analysis. The protein concentrations were
determined using a commercial kit (Protein Assay Rapid kit, Wako
Pure Chemical, Osaka, Japan) and a microplate reader (model 550,
Bio-Rad, Hercules, CA, USA) set at 586 nm with bovine serum al-
bumin as the standard (10).
2.7. Interleukin (IL)-6 and myeloperoxidase (MPO) expression in
the bladder
Interleukin (IL)-6 is an inﬂammatory cytokine while myeloper-
oxidase (MPO) is a marker of neutrophil inﬁltration. The concen-
trations of IL-6 and MPO in whole bladder tissues were measured
using Quantikine ELISA rat IL-6 immunoassay (R6000B, R&D
Systems Inc., Minneapolis, MN, USA) and a rat MPO ELISA
kit(HK105-01, Hycult Biotech, Uden, the Netherlands), respectively
according to the manufacturers' instructions. The absorbance of
eachwell wasmeasured at 450 nm using themicroplate reader. The
tissue IL-6 and MPO levels were normalized to the total protein
contents, and the experiment was performed in groups [1]e[4].
2.8. Data analysis
All the data are presented as the mean ± standard error of the
mean (SEM). Comparisons between groups were performed using a
one-way analysis of variance (ANOVA), followed by the TukeyeK-
ramer test. The histological scores were analyzed using a
nonparametric KruskaleWallis analysis. When differences between
the groups were detected, the group means were compared using
theManneWhitney U test with Bonferroni's correction for multiple
comparison. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. General information from animal groups
The mean body weights of the vehicle-treated CYP, Silod 100-
treated CYP, and Silod 300-treated CYP rats were not signiﬁcantly
different from that of the vehicle-treated saline rats. The mean
bladder weight and the bladder-weight-to-body-weight ratio (BBR)
of the vehicle-treated CYP rats were signiﬁcantly higher than those
of the vehicle-treated saline rats were. Treatment with Silod (both
doses) did not mitigate the CYP-induced increase in bladder weight
and BBR (Table 1).
3.2. Effects of Silod on urodynamic parameters in rats with CYP-
induced cystitis
The representative cystometrogram shown in Fig. 1 revealed
that the vehicle-treated CYP group exhibited ICI, SVV, and BC values
that were signiﬁcantly lower than the respective values in the
vehicle-treated saline group. The ICI and SVV were signiﬁcantly
increased in the Silod 300-treated CYP group compared to those inTable 1
General information in the rat.
Group Vehicle þ Saline Vehicle
Body weight (g) 370.6 ± 10.9 358.8 ±
Bladder weight (mg) 158.3 ± 6.9 256.8 ±
BBR (10e3) 0.43 ± 0.02 0.72 ±
Vehicleþ Saline:Wistar rats treatedwith vehicle (p.o.) and saline (i.p.); Vehicleþ CYP:Wi
with silodosin 100 mg/kg (p.o.) and CYP (i.p.); Silod300 þ CYP: Wistar rats treated w
cyclophosphamide; BBR: Bladder body weight ratio (bladder weight/body weight). D
Vehicle þ Saline group (P < 0.05).the vehicle-treated CYP group. No signiﬁcant differences were
observed in the RV or MVP among the groups (Table 2). Further-
more, a preliminary experiment showed that treatment with Silod
alone at a dose of 300 mg/kg had no effect on urodynamic param-
eters in Wistar rats (data not shown).3.3. Effects of Silod on bladder histology in rats with CYP-induced
cystitis
The bladders of the vehicle-treated CYP rats showed moderate
to severe inﬂammatory changes. In the vehicle-treated saline
group, inﬂammatory cells (leukocytes) weremainly observed in the
vascular lumen, whereas in the vehicle-treated CYP group, leuko-
cytes were mainly observed in the suburothelial and smooth
muscle layers (Fig. 2A). The edema and leukocyte inﬁltration scores
were signiﬁcantly higher in the vehicle-treated CYP group than
those in the vehicle-treated saline group were (Fig. 2B). Treatmentþ CYP Silod100 þ CYP Silod300 þ CYP
14.0 355.6 ± 8.2 383.6 ± 3.7
8.6* 259.6 ± 15.0* 246.4 ± 17.6*
0.02* 0.73 ± 0.03* 0.65 ± 0.05*
star rats treatedwith vehicle (p.o.) and CYP (i.p.); Silod100þ CYP:Wistar rats treated
ith silodosin 300 mg/kg (p.o.) and CYP (i.p.); Vehicle: 0.5% methyl cellulose; CYP:
ata are shown as mean ± SEM in each group. *: Signiﬁcantly different from the
Table 2
Urodynamic parameters in the rat.
Group Vehicle þ Saline Vehicle þ CYP Silod100 þ CYP Silod300 þ CYP
ICI (sec) 174.5 ± 8.5 35.9 ± 3.4* 45.6 ± 4.1* 64.5 ± 6.0*#
SVV (mL) 0.63 ± 0.04 0.10 ± 0.01* 0.13 ± 0.02* 0.18 ± 0.01*#
RV (mL) 0.16 ± 0.02 0.20 ± 0.05 0.21 ± 0.04 0.15 ± 0.05
MVP (cm H2O) 35.0 ± 2.8 39.1 ± 3.3 40.7 ± 2.5 35.8 ± 3.9
BC (mL/cm H2O) 0.090 ± 0.009 0.013 ± 0.002* 0.016 ± 0.004* 0.021 ± 0.006*
Vehicleþ Saline:Wistar rats treatedwith vehicle (p.o.) and saline (i.p.); Vehicleþ CYP:Wistar rats treatedwith vehicle (p.o.) and CYP (i.p.); Silod100þ CYP:Wistar rats treated
with silodosin 100 mg/kg (p.o.) and CYP (i.p.); Silod300 þ CYP: Wistar rats treated with silodosin 300 mg/kg (p.o.) and CYP (i.p.); Vehicle: 0.5% methyl cellulose; CYP:
cyclophosphamide; ICI: intercontraction interval; SVV: single voided volume; RV: post-voiding residual urine volume; MVP: maximum voiding pressure; BC: bladder
compliance. Data are shown as mean ± SEM. *: Signiﬁcantly different from the Vehicle þ Saline group (P < 0.05). #: Signiﬁcantly different from the Vehicle þ CYP group
(P < 0.05).
Fig. 2. Histological effects of silodosin on the bladders of rats with CYP-induced interstitial cystitis. (A) Bladder sections were stained with hematoxylin and eosin (H&E)
(magniﬁcation, 200). The scale bar indicates 100 mm. (B) Histological evaluation was performed according to the procedure in a previous study (12). Veh: vehicle (0.5% methyl
cellulose) (p.o.); CYP: cyclophosphamide. Data are shown as the mean ± SEM. *P < 0.05 compared with the Vehicle þ Saline group.
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edema and leukocyte inﬁltration in the histological assessments
(Fig. 2A and B).
3.4. Effects of Silod on IL-6 and MPO levels in bladder tissue of rats
with CYP-induced cystitis
No signiﬁcant differences were observed in tissue levels of IL-6
among the groups. The bladder tissue levels of MPO were signiﬁ-
cantly higher in the vehicle-treated CYP group than in the vehicle-
treated saline group (Fig. 3A and B). Treatment with Silod at either
100 or 300 mg/kg did not signiﬁcantly alleviate the CYP-induced
elevation of MPO levels in the bladder tissue (Fig. 3A and B).
3.5. Effects of CAP-induced desensitization of afferent nerve
pathway on Silod treatment of CYP-induced cystitis
No signiﬁcant differences were observed in the bladder weight
or BBR among the four groups. The mean number of eye wipes was
signiﬁcantly lower in each CAP-treated group than it was in the
corresponding CAP-untreated group (Table 3). In the CAP-untreatedgroups, treatment with Silod signiﬁcantly prolonged the ICI and
increased the SVV. Moreover, systemic treatment with CAP alone
prolonged the ICI and increased the SVV in the CYP-treated rats.
Silod and CAP treatment signiﬁcantly increased both parameters in
the CYP model. However, treatment with 300 mg/kg Silod did not
affect the ICI and SVV values in the CAP-treated CYP rats. There
were no signiﬁcant differences in the RV, MVP, or BC among the
four groups (Table 4).
4. Discussion
In the current study, the cystometric parameters of the CYP-
stimulated model showed urinary frequency, determined as a
decrease in the ICI and SVV. Furthermore, the MPO levels and
bladder weight were signiﬁcantly higher in the CYPmodel than the
respective values were in the control rats. This observation is in
agreement with the results of a previous study (13). Furthermore,
severe inﬂammatory changes manifested as severe edema and
leukocyte inﬁltration were observed in the CYP model. Pretreat-
ment with Silod partially improved the cystometric parameters but
had no signiﬁcant effect on the CYP-induced bladder inﬂammatory
Fig. 3. Effects of silodosin on IL-6 and MPO levels in CYP-treated rats. (A) IL-6 and (B) MPO levels. Veh: vehicle (0.5% methyl cellulose; p.o.); CYP: cyclophosphamide. Data are
shown as the mean ± SEM. *P < 0.05 compared with the Vehicle þ Saline group.
Table 3
General information in the rat with or without capsaicin treatment.
Group CAP () CAP (þ)
Vehicle þ CYP Silod300 þ CYP Vehicle þ CYP Silod300 þ CYP
Body weight (g) 356.1 ± 8.7 338.0 ± 13.4 337.4 ± 7.8 337.8 ± 4.0
Bladder weight (mg) 259.6 ± 13.8 233.7 ± 13.5 240.7 ± 14.0 229.7 ± 14.0
BBR (10e3) 0.73 ± 0.04 0.69 ± 0.03 0.71 ± 0.03 0.68 ± 0.04
Eye wipe test (times/min) 58.0 ± 3.5 57.2 ± 4.0 11.1 ± 3.0x 10.6 ± 2.3y
CAP (): capsaicin-untreated Wistar rats; CAP (þ): capsaicin-treated Wistar rats; Vehicle þ CYP: Wistar rats treated with vehicle (p.o.) and CYP (i.p.); Silod300 þ CYP: Wistar
rats treated with silodosin 300 mg/kg (p.o.) and CYP (i.p.); Vehicle: 0.5% methyl cellulose; CYP: cyclophosphamide; BBR: Bladder body weight ratio (bladder weight/body
weight). Data are shown as mean ± SEM. x: Signiﬁcantly different from the CAP () treated Vehicle þ CYP group (P < 0.05). y: Signiﬁcantly different from the CAP () treated
Silod300 þ CYP group (P < 0.05).
Table 4
Urodynamic parameters in the rat with or without capsaicin treatment.
Group CAP () CAP (þ)
Vehicle þ CYP Silod300 þ CYP Vehicle þ CYP Silod300 þ CYP
ICI (sec) 44.9 ± 3.3 65.5 ± 5.1x 72.9 ± 4.6x 68.7 ± 6.2x
SVV (mL) 0.14 ± 0.01 0.23 ± 0.03x 0.26 ± 0.02x 0.26 ± 0.03x
RV (mL) 0.29 ± 0.04 0.22 ± 0.06 0.27 ± 0.05 0.24 ± 0.04
MVP (cm H2O) 36.0 ± 2.4 37.5 ± 3.8 36.2 ± 3.8 34.1 ± 3.8
BC (mL/cm H2O) 0.012 ± 0.002 0.022 ± 0.004 0.020 ± 0.002 0.019 ± 0.005
CAP (): capsaicin-untreated Wistar rats; CAP (þ): capsaicin-treated Wistar rats; Vehicle þ CYP: Wistar rats treated with vehicle (p.o.) and CYP (i.p.); Silod300 þ CYP: Wistar
rats treated with silodosin 300 mg/kg (p.o.) and CYP (i.p.); Vehicle: 0.5% methyl cellulose; CYP: cyclophosphamide; ICI: intercontraction interval; SVV: single voided volume;
RV: post-voiding residual urine volume; MVP: maximum voiding pressure; BC: bladder compliance. Data are shown as mean ± SEM. x: Signiﬁcantly different from the CAP ()
treated Vehicle þ CYP group (P < 0.05).
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inﬂammatory effects of Silod or other a1-AR antagonists. Further-
more, to the best of our knowledge, this is the ﬁrst study to show
that Silod has no direct effect on inﬂammation in a CYP-induced
cystitis rat model, whereas it protected against bladder over-
activity. Therefore, we speculated that other mechanisms might be
involved in the amelioration of CYP-induced bladder overactivity
by Silod.
A previous study indicated that CYP-induced bladder hyper-
activity was abolished by systemic pretreatment with CAP, sug-
gesting that bladder inﬂammation alters the activity of CAP-
sensitive bladder afferent neurons (14). In another study in
Wistar rats, pretreatment with systemic CAP signiﬁcantly
reduced the number of Fos-immunoreactive cells in spinal cord
neurons, which were increased by bladder distension after CYP-
induced cystitis (15). Our study also showed that systemic CAP
administration signiﬁcantly decreased the frequency of eye
wiping, which is a nociceptive behavior induced by CAP. This
indicates that CAP treatment inhibited the CAP-sensitive afferent
transmission. Systemic CAP administration prolonged the ICI andincreased the SVV in CYP-treated rats during continuous cyst-
ometry. Moreover, treatment with Silod prolonged the ICI and
increased the SVV in rats that were treated with CYP without CAP
but not in rats treated with both CYP and CAP. These data showed
that no further increase in ICI and SVV occurred following Silod
300 treatment of the CAP-treated group. Previously, Trevisani
et al. reported that a1-ARs are functionally expressed by the CAP-
sensitive afferent primary neuron in the rat urinary tract (4). CAP
has been reported to upregulate the transient receptor potential
vanilloid 1 (TRPV1) receptor level. Matos et al. recently showed
the peripheral a1A-AR stimulation induced bladder pain, and
sensitized TRPV1 and increased ATP from urothelial cells (16).
Another study previously reported that intravenously or intra-
thecally administered Silod increased the bladder capacity in
conscious female SpragueeDawley rats with cerebral infarction
(17). However, this effect was absent in rats that were adminis-
tered resiniferatoxin (RTX), which has a similar effect to that of
CAP (17). The current data suggest that Silod could suppress the
CYP-induced detrusor overactivity by inhibiting the CAP-sensitive
afferent pathway.
N. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 71e7776Afferent nerve projections play a physiological role in the
detection of bladder ﬁlling and the transfer of neuronal signals from
the bladder to the brain, which regulates urination. Primary
afferent ﬁbers from the pelvic nerve predominantly project to the
L6 spinal cord level in rats. The primary bladder afferent pathway
consists of myelinated Ad and unmyelinated C ﬁbers (18). It has
been widely speculated that Ad ﬁbers respond to bladder ﬁlling
under normal conditions, whereas C ﬁbers convey noxious stimuli
in pathological conditions. In contrast, several recent studies have
shown that both Ad and C ﬁbers respond to bladder overactivity
(18,19). A previous report showed that intravesically instilled
acrolein increased the activities of both ﬁbers (18). Additionally,
bladder Ad and C ﬁbers are inﬂuenced by chemical stimuli such as
prostaglandin E2 (19).
TRPV1 receptors are expressed by urothelial cells innervated by
subpopulations of myelinated Ad and unmyelinated C ﬁbers (18,20).
Responses to CAP administration are detected by these sub-
populations of Ad and C ﬁbers (21,22). It has been reported that
systemic treatment with RTX reduced the activity of both ﬁber
types in response to bladder ﬁlling (23) and that TRPV1 is not
normally expressed by Ad ﬁbers but is induced under inﬂammatory
conditions (24). These ﬁndings indicate that the systemic CAP
treatment in the current study may have suppressed the primary
bladder afferent pathway and this effect likely involves Ad and C
ﬁbers in the CYP-induced rat model of cystitis.
a1A- or a1D-ARs in the rat bladder are involved in the activation
of afferent nerve activity. However, the exact mechanism by which
Silod and other a1-AR antagonists affect bladder afferent neurons
in animal models of urinary disorders is not well understood. In a
previous study using urethane anesthesia, intraarterial Silod
inhibited the micturition reﬂex in rats that were intraurethrally
administered prostaglandin E2 via suppression of the urethral C
ﬁber afferent pathway (17). Furthermore, Aizawa et al. demon-
strated that under isovolumetric bladder conditions in normal fe-
male SpragueeDawley rats anesthetized with urethane,
intravenously and intravesically administered Silod or a selective
a1D-AR antagonist, BMY7378 inhibited the afferent nerve activity
of bladder Ad but not C ﬁbers (3). A limitation of our current study is
that in evaluating the effects of Silod, wewere unable to distinguish
between Ad and C ﬁbers and, therefore, the exact ﬁber population
affected by Silod remains unclear. Moreover, a1-AR subtypes (a1A,
a1B, and a1D) are present in the bladder urothelium, lamina
propria, and bladder vessels in the rat, but it is not clear which
subtypes are involved in afferent signaling (3,17,25). We previously
reported that chronic treatment with Silod suppresses detrusor
overactivity by increasing the bladder blood ﬂow in spontaneously
hypertensive rats (10). Based on these data, the effects of Silod on
the urothelium, laminar propria, and bladder vessels in the CYP-
induced rat model of cystitis should be investigated. Further
studies are needed to elucidate the mechanism by which a1-AR
antagonists ameliorate detrusor overactivity.
In conclusion, the current study has demonstrated that pre-
treatment with Silod partially improved urinary frequency but not
inﬂammatory responses in the CYP-induced rat model of cystitis.
Furthermore, Silod showed no effect on the ICI or SVV in the CAP-
treated CYP rats. Therefore, Silod might inhibit CYP-induced
detrusor overactivity by inhibiting the CAP-sensitive afferent
pathway but not by an anti-inﬂammatory effect on the bladder.Conﬂict of interest statement
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